Atlas Trials

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Clinical trial NCT05970289 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05970289
Sponsor
Brii Biosciences Limited
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Hepatitis B Virus Infection
Start date
2023-08-22
Primary completion
2025-07-16
Enrollment
86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.